BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 2472198)

  • 1. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
    Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
    Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
    Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
    Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies.
    Vuist WM; van Buitenen F; Hekman A; Melief CJ
    Cancer Res; 1990 Sep; 50(18):5767-72. PubMed ID: 1697500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.
    Hooijberg E; Sein JJ; van den Berk PC; Hart AA; van der Valk MA; Kast WM; Melief CJ; Hekman A
    Cancer Res; 1995 Jun; 55(12):2627-34. PubMed ID: 7540106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
    Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS
    Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
    Masui H; Moroyama T; Mendelsohn J
    Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.
    Kaminski MS; Kitamura K; Maloney DG; Campbell MJ; Levy R
    J Immunol; 1986 Feb; 136(3):1123-30. PubMed ID: 3484499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins.
    van Oosterhout YV; van den Herik-Oudijk IE; Wessels HM; de Witte T; van de Winkel JG; Preijers FW
    Cancer Res; 1994 Jul; 54(13):3527-32. PubMed ID: 7516821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
    de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
    Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2.
    Berinstein N; Levy R
    J Immunol; 1987 Aug; 139(3):971-6. PubMed ID: 3496394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
    Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
    Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
    Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR; Klarnet JP; Peace DJ; Cheever MA; Badger CC; Bernstein ID; Greenberg PD
    Cancer Res; 1990 Sep; 50(17):5421-5. PubMed ID: 2386946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model.
    Velders MP; van Rhijn CM; Briaire IH; Fleuren GJ; Warnaar SO; Litvinov SV
    Cancer Res; 1995 Oct; 55(19):4398-403. PubMed ID: 7671252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate.
    LeBerthon B; Khawli LA; Alauddin M; Miller GK; Charak BS; Mazumder A; Epstein AL
    Cancer Res; 1991 May; 51(10):2694-8. PubMed ID: 2021947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
    Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
    Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2.
    Epstein AL; Khawli LA; Hornick JL; Taylor CR
    Cancer Res; 1995 Jun; 55(12):2673-80. PubMed ID: 7780984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antitumor effects of interleukin 2 and the monoclonal Lym-1 against human Burkitt lymphoma cells in vitro and in vivo.
    Gill I; Agah R; Hu E; Mazumder A
    Cancer Res; 1989 Oct; 49(19):5377-9. PubMed ID: 2788499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.